Italia markets closed

Arch Therapeutics, Inc. (ARTH)

Other OTC - Other OTC Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,18000,0000 (0,00%)
In data: 11:20AM EDT. Mercato aperto.
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente1,1800
Aperto1,1800
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno1,1800 - 1,1800
Intervallo di 52 settimane0,3900 - 18,0000
Volume211
Media Volume4.941
Capitalizzazione5,596M
Beta (5 anni mensile)3,56
Rapporto PE (ttm)N/D
EPS (ttm)-1,4000
Prossima data utili20 mag 2024 - 24 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Arch Therapeutics Provides AC5® Commercialization Update

    Orders and Paid Claims Increasing Since Rollout of Reimbursement CodeFRAMINGHAM, Mass., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided a commercialization update on the Company’s first product, AC5® Advanced Wound System. Since the Centers for Medicare and Medicaid Services (“CMS”) established A2020, a Level II Healthcare Common Procedure Codi

  • GlobeNewswire

    Arch Therapeutics Completes Financing as Bridge to Uplisting

    Common Stock Listing on National Exchange is Next Planned Significant MilestoneFRAMINGHAM, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that it completed a private placement with institutional and accredited individual investors (collectively, the “Investors”) as a Bridge Offering preceding a planned national exchange listing of the

  • GlobeNewswire

    Arch Therapeutics to Present AC5® Advanced Wound System at 2023 Symposium on Advanced Wound Care (“SAWC”)

    SAWC Spring 2023 represents first clinical conference opportunity to introduce newly effective dedicated AC5 HCPCS reimbursement codeFRAMINGHAM, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that the Company will be exhibiting its AC5® Advanced Wound System (“AC5”) at the Symposium on Advanced Wound Care (“SAWC”) Spring 2023, which ta